RNS & Investor News

Launch of extended range of LPLDL® and SlimBiome® products at Vitafoods 2018

08 May 2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, and diabetes announces that it will be presenting an extended range of products and presenting new research data on its LPLDL® and SlimBiome® products at the Vitafoods European tradeshow in Geneva from the 15-17 May 2018. The event provides the opportunity to connect with 16,500 industry decision makers from the supplements, nutraceutical, functional food and beverage industries and is viewed as one of the world's leading trade fairs for the food and drinks industry.

LP-LDL®

OptiBiotix will be showcasing its LPLDL® probiotic for the reduction of high cholesterol and high blood pressure in a number of new product concepts with its global manufacturing partner Sacco S.r.l.  In addition to an exhibitor presence, the Company will be presenting further results of its human studies in an abstract and poster titled "Lactobacillus plantarum LPLDL® reduces cholesterol in adults with normal to mildly elevated cholesterol. ". 

LPLDL® has gone through a successful commercial development since its launch at VitaFoods in May 2017 announcing seven manufacturing, application and distribution commercial agreements. The unique ability of LPLDL® to reduce both high cholesterol and high blood pressure has attracted a lot of media and industry attention leading to LPLDL® being shortlisted as 'Probiotic Product of the Year' at the show.

SlimBiome®

OptiBiotix will be showcasing its award winning SlimBiome® presented in a range of new product concepts which include natural fruit gummies, muesli pots, Nutri-Bites® and flavours for new bars. In addition to an exhibitor presence, the Company will be presenting results of its humans studies on SlimBiome® carried out by Oxford Brookes University. The study will be presented as an abstract and poster titled "SlimBiome reduces hunger and food cravings in healthy overweight and obese adults".  The study shows that if you compare control and test groups who take SlimBiome® or a placebo the SlimBiome® group:-

  • Feel fuller and are less hungry
  • Have less food cravings
  • Change their food choice so eat less sweet or fatty foods

Following on from winning the award for 'Best Functional Ingredient for Health and Well Being' at Food Matters in November 2017, SlimBiome® has been shortlisted for the award of 'Ingredient of the Year: Weight Management'.  

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased to be attending Vitafoods with a range of new products, new human studies on SlimBiome® and a growing list of industry partners. We are confident that our participation at VitaFoods will help progress existing discussions with corporate partners and open up opportunities in new territories for the manufacture and distribution of our growing range of products. Having both SlimBiome® and LPLDL® nominated for such prestigious industry awards will help attract commercial interest in our technology and products. Finally, we are really excited by the results of the human study on SlimBiome® which supports our scientific understanding of its mechanism of action, independent consumer surveys and all the success stories we receive from customers who use our GoFigure® products containing SlimBiome® to help manage their weight. Having a product with scientific data, which shows it helps to reduce hunger and snacking and most importantly changes a users food choice so they eat less sweet and fatty foods, is really exicting. Hunger free dieting is now a consumer option and we hope that our wider range of products containing this unique formulation will help bring the benefits of SlimBiome® technology to a wider international audience."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O´Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
   
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner  
   
finnCap (Broker) Tel: 020 7220 0500
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Abigail Wayne (Corporate Broking)
 
   
Walbrook PR Ltd
Anna Dunphy
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.